News Snapshot:
Chinese drug developer Abbisko files for HK IPO Larissa Ku PE-backed Abbisko Therapeutics, which focuses on the discovery and development of innovative and differentiated small molecule oncology therapies, has filed for a Hong Kong IPO. The largest institutional shareholder is Lilly Asia Ventures (LAV) with an 11.16% stake, followed by Qiming Venture Partners and Elbrus Investments, a subsidiary of Temasek Holdings, with 8.65% and 8.28%,...
